Skip to main content

Table 3 Patient characteristics in subgroups according to age >/≤ 65 years

From: Clinical characteristics and blood/serum bound prognostic biomarkers in advanced pancreatic cancer treated with gemcitabine and nab-paclitaxel

 

≤65

(n = 36)

> 65

(n = 39)

p-value

Female

18 (50)

16 (41)

0.435

Prior Surgery

10 (28)

17 (44)

0.154

Localised disease/M0

7 (19)

15 (38)

0.070

CA19–9(median)a

980

476

0.057

ECOG 0

17 (47)

16 (41)

0.589

ECOG 1

17 (47)

19 (49)

0.897

ECOG 2

2 (6)

4 (10)

0.453

Adjuvant chemotherapy

8 (22)

16 (41)

0.081

Neoadjuvant chemotherapy

2 (6)

1 (3)

0.509

S-albumin (mean)

37.7

36.6

0.335

S-albumin (median)

39

37

0.203

N cycles (median)

3

5

0.061

Thrombocytopenia

21 (58)

27 (69

0.326

BM-toxicity G3–4

9 (25)

14 (36)

0.307

Dose intensity Gem (mean)

79%

73%

0.214

Dose intensity NabP (mean)

75%

63%

0.028

Full dose

25%

10%

0.092

2nd line treatmentb

45%

55%

0.438

  1. Number (%) where not otherwise stated. aDropouts were 5 and 3 in the young and elderly group, respectively. bDropouts were 5 and 10 in the young and elderly group, respectively. Statistical significance at the 0.05 level marked in bold text.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us